Abiraterone Acetate , ≥99% , 154229-18-2

Synonym(s):
17-(Pyridin-3-yl)androsta-5,16-dien-3β-yl acetate;Abiraterone acetate;CB 7598

CAS NO.：154229-18-2

Empirical Formula: C26H33NO2

Molecular Weight: 391.55

MDL number: MFCD00934213

EINECS: 620-314-7

PRODUCT Properties

• Melting point: 127-130°C
• Boiling point: 506.7±50.0 °C(Predicted)
• Density: 1.14±0.1 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: Chloroform (Slightly), DMSO (Sparingly), Methanol (Sparingly)
• pka: 5.31±0.12(Predicted)
• form: powder
• color: white to beige
• InChIKey: UVIQSJCZCSLXRZ-UBUQANBQSA-N
• SMILES: C1[C@@]2(C)C(=CC[C@]3([H])[C@]2([H])CC[C@]2(C)C(C4=CC=CN=C4)=CC[C@@]32[H])C[C@@H](OC(=O)C)C1

Description and Uses

In April 2011, the United States FDA approved abiraterone acetate (CB7630) in combination with the steroid prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for patients who were previously treated with a docetaxel containing regimen for late-stage disease. Abiraterone acetate affects prostate, testicular, and adrenal androgens by irreversibly inhibiting both the lyase and hydroxylase activity of cytochrome P450 17A (CYP17) signaling pathways (IC_50's of 2.9 and 4 nM, respectively) thereby decreasing testosterone levels.Most common serious adverse events for abiraterone acetate versus placebo included fluid retention (30.5% vs. 22.3%), hypokalemia (17.1% vs. 8.4%), hypertension (9.7% vs. 7.9%), hepatic transaminase abnormalities (10.4% vs. 8.1%), and cardiac abnormalities (13.3% vs. 10.4%).

A novel steroidal inhibitor of human Cytochrome P450(17a-Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H360-H372
• Precautionary statements: P201-P202-P260-P264-P270-P308+P313
• WGK Germany: 3
• RTECS: BV7992100
• HS Code: 2937290000